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Abstract
Compounds that delay aging might also postpone age-related diseases and extend healthspan in humans. Icariin is a
flavonol extracted from several plant species of the Epimedium family. The icariin and its metabolic derivatives have been
shown to exert wide protective effects in age-related diseases. However, whether icariin and its derivatives have the
potency of delaying aging remains unclear. Here, we report that icariin and its derivative icariside II extend C. elegans
lifespan. Using HPLC, we found high level of icariside II in the animals treated with icariin, suggesting icariside II is the
bioactive form in vivo of icariin. Icariside II also increased the thermo and oxidative stress tolerance, slowed locomotion
decline in late adulthood and delayed the onset of paralysis mediated by polyQ and Ab1–42 proteotoxicity. The lifespan
extension effect of icariside II is dependent on the insulin/IGF-1 signaling (IIS) since the daf-16(mu86) and daf-2(e1370) failed
to show any lifespan extension upon icariside II treatment. Consistently, icariside II treatment upregulates the expression of
DAF-16 targets in the wild-type. Moreover, our data suggests that the heat shock transcription factor HSF-1 has a role in
icariside II-dependent lifespan extension further implicating the IIS pathway. In conclusion, we demonstrate a novel natural
compound, icariside II as the bioactive form of icariin, extends the healthspan via IIS pathway in C. elegans.
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Introduction
A major goal of current research on aging is to identify
compounds that delay age-related diseases and extend healthspan
in humans. Herba epimedii is a popular herbal tonic used in traditional
Chinese medicine, with proven efficacy in treating several age-
related diseases including osteoporosis, cardiovascular diseases,
neurodegenerative diseases and sexual dysfunction [1,2]. Icariin is
the major pharmacologically active flavonol diglycoside of Herba
epimedii. Various studies indicate the anti-oxidative effect of icariin on
DNA damage, b-amyloid mediated neurotoxicity, and vein
endothelial cell oxidative injury [1]. Meanwhile, icariin and its
derivatives function assignalingmodulators to exertbeneficial effects
in a multitude of age-dependent disease states, including bone loss,
cancer, cardiovascular disease, and neurodegenerative disorders
[3,4,5,6]. However, whether icariin and its derivatives own the
potency of slowing aging remain elusive. Our previous studies on
Epimedium Flavones(EF), theraw extractof Epimedium which contains
icarrin as a majorconstituent,show thatEFdelaysaging inDrosophila
melanogaster and Caenorhabditis. elegans [7,8]. Interestingly, EF also
resets the age-related metabolites (fatty acids, carnosine, ergothio-
neine and deoxycholic acid et al) to the juvenile level in rat plasma
and urine [9,10]. These findings further prompted us to investigate
the anti-aging potential of icariin and its derivatives.
The experimental organism, Caenorhabditis elegans is a well-
established aging model, sharing similar aspects of aging with
mammals, such as sarcopenia and locomotion decline [11]. C.
elegans has provided critical insight on conserved lifespan-regulated
pathways, for example insulin/insulin-like growth factor signaling
(IIS) [12], making C. elegans a model system to identify novel
genetic links and compounds that can promote healthy aging in
humans.
The highly conserved IIS pathway plays a key role in aging. It
has been demonstrated in multiple species that inhibition of the
IIS pathway extends lifespan [12]. In C. elegans, the daf-2 gene
encodes an insulin/IGF-1 receptor. Mutations in daf-2 suppress
the IIS which lead to the nuclear localization of FOXO/DAF-16
transcription factor. The activated FOXO/DAF-16 regulates a
series of genes involved in lifespan control, stress tolerance and
protein misfolding suppression [13,14]. Nuclear localization of
DAF-16 in the daf-2 mutants requires the heat shock transcription
factor (HSF)-1, which modulates the expression of heat shock
proteins and protease responsible for the stress tolerance and
protein folding [15]. Despite the well established role of a number
of genes in the IIS pathway in modulating aging, pharmacological
tools that inhibit IIS pathway to extend lifespan are not commonly
available, which limits its translation to mammalian model
systems.
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e28835In this study, we tested the anti-aging properties of icariin and
its three derivatives, icariside I, icariside II and icaritin in C. elegans.
We found that icariin and one of its derivatives, icariside II
prolonged adult lifespan. Chemical profiles of icariin treated
animals revealed that icariside II was the predominant bioactive
form of icariin in vivo. Additionally, we found that icariside II
treated animals have delayed age-associated phenotypes suggesting
icariside II enhances the healthy aging significantly. Finally, our
genetic analysis indicates that Icariside II may act through the IIS
pathway to affect C. elegans lifespan.
Results
Icariin and its active metabolite icariside II extend C.
elegans lifespan
We tested icariin for anti-aging properties using wild type C.
elegans animals. Considering the low bioavailability of icariin, we
chose to grow the worms in a liquid medium which has been
shown to be more efficient for drug delivery [16]. C. elegans N2
worms were exposed to icariin from day 1 of the young-adult stage
till their death. Three different concentrations of icariin were used
viz. 15, 45 and 75 mM. Icariin increases lifespan significantly in a
dose-dependent manner (Figure 1B), and among the concentra-
tions examined, 45 mM had the greatest effect on longevity,
extending adult mean lifespan by up to 20.67% at 25uC (Figure 1B,
Table S1). Worms exposed to either higher or lower concentra-
tions of icariin showed a smaller or an insignificant life extension
(Figure 1B, Table S1).
It is well known that the flavonoids obtained from plants are
often not the bioactive forms [17]. Pharmacokinetic analysis show
that after oral administration, icariin is metabolized to icariside I,
by hydrolyzing the C-3-O-Rhamnopyranoside (R1) moiety; to
icariside II by hydrolyzing C-7-O-Glucopyranoside (R2) moiety,
and to icaritin by the hydrolysis of both the R1 and R2 moieties
(Figure 1A). To determine whether the metabolites harbor anti-
ageing properties, we tested lifespan effect of these three
metabolites in C. elegans in parallel with icariin. Neither icariside
I nor icaritin showed any significant effect on longevity (Fig. S1A,
B; Table S1). However, treatment with icariside II resulted in a
lifespan extension similar to that caused by icariin (Figure 1C,
Table S1). 20 mM of icariside II treatment is sufficient to cause a
lifespan extension similar to 45 mM icariin, suggesting that
icariside II might be the bioactive form of icariin in vivo
(Figure 1D). To investigate this, we measured the internal levels
of icariin and its derivatives in wild type C. elegans by High-
Performance Liquid Chromatography. Worms were treated with
the 45 mM icariin for four days starting at day 1 of young–adult
stage. The compounds found in worms were mainly icariside II
and icariin (Figure 1E). The level of icariside II was higher than
icariin (icariin 0.1811 mg; icariside II 0.3154 mg). Icariside I and
icaritin were not detected, thus, icariside II is likely to be the
primary bioactive structure that possesses anti-aging properties in
C. elegans. For the remainder of the study, we have used icariside II
and the experiments with icariin are presented in the supplemental
information.
Icariside II treatment promotes stress resistance and
locomotion in C. elegans
There is a striking correlation between stresses-resistance and
lifespan extension. Compounds that extend lifespan might be
associated with improved survival under conditions of heat or
oxidative stress. To explore whether icariside II can protect C.
elegans against vulnerability to stress, we performed the heat stress
and oxidative stress resistance assays. In both these assays, N2
hermaphrodites were pre-treated with Dimethyl sulfoxide
(DMSO) control or 20 mM icariside II for four days starting at
day 1 of young-adult stage at 25uC. Thermotolerance assay was
tested at 35uC. Worms were counted every two hours. As shown in
Figure 2A, the worms pre-exposed with 20 mM icariside II live
significantly longer than the control worms (mean survival time;
control, 9.7 hrs; icariside II, 11.3 hrs). A similar protective effect in
thermotolerance was also observed upon icariin treatment (Figure
S2). In oxidative stress resistance assay, worms were washed at
least three times with S basal buffer to exclude the possibility of
drug interaction with hydrogen peroxide. Then animals were
soaked in hydrogen peroxide (10, 15 or 20 mM) for 2 hrs,
transferred to NGM to allow recovery and then scored after
16 hrs. Icariside II pre-treatment afforded dramatic protective
effect in the mild (10 mM H2O2) and moderate (15 mM H2O2)
oxidative stress (Figure 2B; survival percentages; mild, control,
42.8%; icariside II, 74.5%; moderate, control,18%; icariside II,
30.3%).
A major feature of aging is a reduction in muscle strength from
sarcopenia, which impairs physical ability and reduces the quality
of late life significantly. In C. elegans, the swimming bends are a
locomotive phenotype which progressively declines with age,
indicating physical deterioration of muscle [11]. Wild type N2
were treated with DMSO control or 20 mM icariside II starting
from day 1 of young-adult stage. Swimming bends were counted at
day 4, which is the beginning of the middle life of N2, and at day
10, which is the start point of the death phase. Our results show
that icariside II treated group reduced the decline in swimming
prowess at old age (Figure 2C). The number of swimming bends in
icariside II treated group is statistically indistinguishable from
DMSO control group at day 4 of adulthood. However, the
difference in swim vigor is apparent at day 10 (control, 7.760.8;
icariside II, 12.861.4). In order to testify the sarcopenia more
directly, we employed a MYO-3::GFP-NLS transgenic strain
PD4251. In this strain, the GFP reporter is located in the muscle
nuclei, and aging-related deterioration of C. elegans body wall
muscle is indicated by GFP fluorescence decline [18]. As shown in
Figure 2D, GFP labeled nuclei dimmed with aging compared day
4 adults to day 10 adults in control, while 20 mM icariside II
treatment reduced the decline of the fluorescence significantly. We
quantified GFP nuclei in 15 randomly selected animals in the
control and drug treated group at day 4 and day 10. Icariside II
treatment was found to delay the decline of quantitation of GFP
labeled muscle nuclei significantly (Figure 2E). Together with the
swimming assay, these results indicated that both muscle function
and integrity are preserved longer by treatment with the
compound.
Icariside II ameliorates protein aggregation and
protetoxicity-mediated paralysis phenotype
Aggregation of misfolded proteins increases with aging and
causes a chronic proteotoxic stress which is the main reason for a
variety of age-related neurodegenerative diseases, such as
Parkinson’s disease and Alzheimer’s disease [19]. As icariin has
a protective effect under conditions of thermal and oxidative stress,
we investigated if icariside II can also ameliorate internal
proteotoxic stress in C. elegans. Two C. elegans models of human
proteotoxic diseases were exploited here: the strain CL4176
(dvIs27[pAF29(myo-3/Ab 1-42/let UTR) + pRF4(rol-6(su1006)]) [20]
and AM140 (rmIs132[P(unc-54) Q35::YFP]) [21]. The strain
CL4176 is engineered to provide temperature-inducible muscle
expression of a human b-amyloid peptide (Ab) transgene, resulting
in a readable paralysis phenotype of Ab toxicity upon temperature
upshift to 25uC [20]. The strain AM140 contains a YFP fusion
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muscle cells which forms aggregates and causes mobility loss as
animals age [21]. The accumulation of Ab is considered to be the
central event triggering neuron degeneration in Alzheimer’s
disease, and polyQ aggregation is a feature in several neurological
conditions. We analyzed the age-dependent formation of polyQ
aggregation in DMSO control and drug treated animals. Q35-
GFP animals were treated with DMSO control or 20 mM icariside
II starting from late L4 stage in NGM at 20uC. Fluorescent images
were taken at day 4 and day 6 in adulthood. The representative
images are presented at Figure 3A as indicated time points. 15
worms were selected randomly for quantification of the aggregates
in each group. We found that 20 mM icariside II treatment
reduced the formation of polyQ aggregates at day 4 (Figure 3B)
Figure 1. Icariin and its bioactive form icariside II extend lifespan in C. elegans. A. Chemical structures of icariin and its derivatives. The
common structure is 8-prenylkaempferol. R1 and R2 are substituted by rhamnose (rha) or glucose. Removal of R1 (Rha) results in icariside I, while
removal of R2 results in icariside II. Removal of both R1 and R2 results in icaritin. B. Survival curves of N2 hermaphrodites treated with DMSO control
or icariin (15, 45 and 75 mM) from day 1 adulthood to death at 25uC. Maximum increase in lifespan was observed at 45 uM. C. Survival curves of N2
treated with DMSO control or icariside II (10, 20 and 40 mM). Maximum increase in lifespan was observed at 20 mM. D. Optimum dosage-response
analysis of icariin (45 mM) and icariside II (20 mM). Icariside II treatment induces the similar extension with relatively lower dosage compared to icariin.
E. HPLC profiles of icariin and icariside II in N2 treated with 45 mM icariin for 4 days initiated from day 1 in adulthood. HPLC detects high level of
icariside II in vivo. Small figures (insert) are HPLC profiles of standard samples of icariin and icariside II. All the data above came from 1 representative
experiment. For lifespan assay, the treatments were started at day 1 in adulthood continuing to death. Statistical detail and repetitions of the
experiments were summarized in Table S1.
doi:10.1371/journal.pone.0028835.g001
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dependent paralysis was also significantly postponed in AM140
treated with icariside II (Figure 3C). Same effect was also observed
with icariin treatment (Figure S3). Using the Ab1–42 muscle model,
we checked whether icariside II protects against Ab-induced
toxicity in vivo. Synchronized eggs or L3 larvae were treated with
DMSO control or 20 mM icariside II and the treatment was
continued for next 60 hrs (for eggs) or 36 hrs (for L3). Ab
induction was induced at L3 stage when the temperature was shift
to 25uC. Paralysis at several time points was monitored. A
significant delay in paralysis was observed in the transgenic
animals with icariside II treatment in both time durations
(Figure 3D, egg-duration; Figure 3E, L3-duration), suggesting
that icariside II treatment can alleviate the Ab toxicity and short
time treatment (L3-duration) is sufficient to reduce the toxicity.
Icariside II treatment extends lifespan via IIS pathway
Down regulation of the insulin signaling pathway increases C.
elegans lifespan, stress tolerance, locomotory healthspan and
resistance to proteotoxicity in a FOXO/DAF-16 dependent way
Figure 2. Icariside II promotes stress resistance and slows age related decline in movement in C. elegans. A. Icariside II pre-exposure
elevated the N2 adults’ survival significantly under thermostress. Animals were pre-treated with the DMSO control (1%) or 20 mM icariside II starting
from day 1 adulthood for four days. Shown is the combination of two replicates. Mean survival time, DMSO control, 9.7 hrs; icariside II, 11.3 hrs.
Animals tested: 87 (DMSO control); 95 (icariside II). P=0.0151 (Log-rank (Mantel-Cox) Test). B. Pre-treatment with icariside II increased oxidative stress
resistance significantly. Day 1 wild type adults were treated with DMSO control or 20 mM icariside II for 4 days and then soaked in different
concentrations of H2O2 (10, 15, 20 mM) for 2 hrs. Survival percentages were scored after a 16 hours recovery window in regular NGM. Shown are
average survival percentages in 3 experiments with 30–50 animals/experiment. Total number of animals tested: 102 (DMSO Control), 113 (icariside II
20 mM); error bars indicate SEM among three independent experiments; t-test,
*P,0.05. C. Treatment with icariside II extends swimming healthspan
in advanced age; Average swimming bends per 30 seconds in 15 animals were scored in two independent trials; error bars indicate SEM among
individual animals scored; t-test,
**P,0.01. D. Icariside II treatment slows the age-related deterioration of C. elegans body wall muscle. Age-related
deterioration of C. elegans body wall muscle is indicated by GFP fluorescence decline of a pmyo-3NLS::GFP fusion in the strain PD4251. Representative
images of whole-animals treated with DMSO control and icariside II are presented at the ages indicated (25uC). E. Quantitation of the number of
fluorescent nuclei in PD4251 treated with DMSO or icariside II. 15 animals of each strain were scored in two independent trials. Error bars indicate SEM
among individual animals scored; t-test,
***P,0.001.
doi:10.1371/journal.pone.0028835.g002
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acting through the IIS pathway, the lifespan assay was performed
in a daf-16 null mutant strain. We found that daf-16(mu86) mutants
raised on 20 mM icariside II did not live longer than the DMSO
control group (Figure 4A, Table. S2). To gain further insight into
the function of icariside II in life span extension by the IIS
reduction, we examined the effects of icariside II on the life span in
daf-2(e1370) mutant. Icariside II fails to lengthen the lifespan in the
daf-2 allele (Figure 4A, Table. S2). Together, these results suggest
that the life span extensions mediated by icariside II are involved
in IIS pathway. The same effect was also observed in icariin
treatment (Figure S4).
To ascertain the effect of icariside II on the IIS-DAF-16
pathway, we examined mRNA levels of sod-3 and hsp-12.3, two
genes which are activated by DAF-16. SOD-3 is a mitochondrial
superoxide dismutase that is involved in oxidative stress resistance
and is one of the direct targets of DAF-16 [22]. HSP-12.3 is a
small heat shock protein that is activated by DAF-16 at the
transcriptional level [22,23]. We found that sod-3 and hsp-12.3
mRNA levels were increased significantly by treatment of 20 mM
icariside II for four days starting at day 1 in adulthood (Figure 4B).
And in a SOD-3::GFP reporter transgenic CF1553, icariside II
treated group showed higher GFP intensity (Figure 4C). Quan-
titation of the relative intensity in western blot analysis of GFP in
Figure 3. Icariside II ameliorates protein aggregation and protetoxicity-mediated paralysis phenotype. A. Representative images of the
whole-animal of Q35-YFP (Q35) transgenic strain AM140 treated with DMSO or icariside II from forth-stage larvae at 20uC are shown. AM140 shows an
increasing aggregation phenotype age-dependently. Icariside II treatment slows the aggregation process obviously. B. Quantitation of the number of
the fluorescent aggregation in AM140 treated with DMSO or icariside II. 15 animals of each strain were scored in two independent trials. Error bars
indicate SEM among individual animals scored; t-test,
***P,0.001. C. Age associated paralysis caused by Q35 expression is significantly reduced in
icariside II treated animals relative to DMSO control animals. Animal were treated under the conditions from forth-stage larvae until paralysis. Shown
is the representative of two replicates. n=38 (control); 37 (icariside II) animals, P=0.0151 (Log-rank (Mantel-Cox) Test). D. The paralysis phenotype
associated with muscle Ab1–42 expression is suppressed by 20 mM icariside II treatment from hatching and E. L3 in the transgenic strain CL4176.
Shown is the non-average paralysis percentages in 3 independent experiments with 30–50 animals/experiment in indicated time points after
temperature upshift to 25uC; error bars indicates SEM among the non-paralysis percentages of three independent experiments; total number of
animals tested: 112 (DMSO Control), 133 (icariside II 20 uM); t-test,
*P,0.05,
**P,0.01.
doi:10.1371/journal.pone.0028835.g003
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group (Figure 4D). These findings provide further evidence that
the effects of icariside II acts through IIS pathway.
HSF-1 is a master transcriptional regulator of stress-inducible
gene expression and protein folding homeostasis [19]. It acts
together with DAF-16 to activate the expression of downstream
genes, promoting the longevity in daf-2 mutant [15]. The HSF-1 is,
at least in part, involved in IIS pathway to regulate lifespan, stress
resistance and proteotoxicity [24]. We tested the effects of icariside
II in hsf-1(sy441) mutant. As indicated in Figure 4E and Table S2,
the lifespan extension was losted in hsf-1 (sy441), suggesting that
the effect of icariside II maybe also HSF-1 dependent.
Icariside II does not function as DR mimetic
Dietary restriction (DR), the reduction of available nutrients,
extends lifespan in diverse organisms from yeast to mammals. It is
possible that icariside II may decrease the food intake or interrupt
the DR-dependent pathways to extend lifespan. To examine the
hypothesis, we performed lifespan assay in eat-2 (ad1116) mutant, a
well-established genetic DR model [25]. Icariside II treatment
caused similar lifespan extension in eat-2 mutant as in N2 starting
at day1 in adulthood (Figure 5A, Table S3). Target of rapamycin
(TOR) is an evolutionarily conserved nutrient-sensing kinase
which plays a dominant role during DR [26]. Here, our results
showed that icariside II extended lifespan in rsks-1 (ok1255) mutant
Figure 4. Increased lifespan in C. elegans by Icariside II treatment is dependent on the insulin/IGF-1 signaling. A. Survival curves of N2,
daf-2(e1370), and daf-16(mu86) hermaphrodites treated with DMSO control or 20 mM icariside II are shown. Icariside II treatment does not increase the
life span in daf-2(e1370) and daf-16(mu86) mutant but extends the life span in N2. This is the representative of 3 independent experiments with
similar results. Detailed parameters are presented in Table S2. B. Icariside II increases the mRNA expression of FOXO/DAF-16 targets hsp12.3 and sod3
significantly. Shown is the representative of three independent experiments with similar results. Error bars indicate SEM among three replicates in
qRT-PCR; t-test,
***P,0.001. C. Representative images of the whole-animal of SOD-3::GFP transgenic strain CF1553 treated with DMSO or 20 uM
icariside II from day 1 in adulthood to day 4 are shown. Icariside II increased the GFP fluorescence significantly compared to DMSO control. D. Western
blot analysis shows an increase of GFP induced by 20 uM Icariside II treatment in SOD-3::GFP transgenic strain CF1553. Picture shown is the
representative of three independent experiments with similar results. Levels shown are the average relative density level in 3 experiments; error bars
indicate SEM among the density level of three experiments; t-test,
**P,0.01. E. Effect of icariside II is HSF-1 dependent. Survival curves of hsf-1 (sy441)
treated with DMSO control and 20 uM icariside II are shown. Icariside II did not increase the lifespan in hsf-1 (sy441) mutant.
doi:10.1371/journal.pone.0028835.g004
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ribosomal subunit S6 kinase (S6K) in C. elegans. Together, these
results indicate that icariside II is unlikely to act as a DR mimetic.
Discussion
After several decades of efforts, biologists involved in research
on aging have produced numerous genes that have been identified
to regulate lifespan. Most of them have been associated with a few
highly conserved pathways like IIS, TOR pathway, AMP kinase
pathway et al [12]. Since the discovery of these aging-associated
pathways, studies have been performed to uncover pharmaceutical
agents that could modify their function. A quantity of anti-aging
compounds have been reported: the inhibitor of TOR pathway
rapamycin [27], an AMP kinase activator metformin [28], a range
of antioxidant agents like vitamin E [29], and a series of
antidepressants [30] and anticonvulsants [31]. It is also noteworthy
that a group of aging-linked naturally-occurring products
belonging to the flavonoid family has been discovered. This group
includes compounds like resveratrol, quercetin, catechin, curcu-
min, a proanthocyanid-rich fraction from blueberry extract and
green tea polyphenols [32,33]. These flavonoids have been shown
to extend lifespan and delay the onset of aging-related diseases.
And these studies highlight that the flavonoid family as an
invaluable resource for the identification of anti-aging compounds.
Here, we show that icariin, a flavonol of the herb tonic Herba
epimedii, along with icariside II, its bioactive form in vivo, extends
the healthspan in C. elegans. We also demonstrate that icariin and
icariside II act on the well conserved IIS in aging which
strengthens its potential in delaying aging in mammalian system.
In the past, the beneficial effects of flavonoids have mainly been
attributed to protection against oxidative stress. However, recent
indications point towards a signaling modulator function of
flavonoids [17]. Previously studies suggest flavonoids, including
icariin, are extensively metabolized in vivo, resulting in a significant
alteration in their redox potentials [34,35]. Furthermore, our
results show that the C-3-O- Rha moiety is essential for the effect
of lifespan extension although the Rha and Glu moieties exert
similar redox potentials based on structural analysis [17]. One
explanation is that the 39 position of glycoside may be important
for the biological activity of icariin. Many studies show that
aglycone form is the main bioactive form of flavonoid [17].
Though icaritin is the aglycone form of icariin, it did not show any
effect on lifespan regulation in C. elegans in our study (Figure S1B).
This reflects the complexity of the action modes of flavonoids as
signaling modulators, and the structure-dependence of the effects.
Variations have been existed in the effects of lifespan extension
upon flavonoid treatment. For example, Epigallocatechin-3-gallate
has been shown to induct a prolongation of C. elegans life span in
one studies while did not promote longevity in the other two
studies [32]. The unstable effects of flavonoid in the longevity
tested in C.elegans may be caused by several possibilities. One
major explanation is the poor absorption and low bioavailability of
flavonoids in vivo [17]. As indicated by the one of the resveratrol
study which shows the lost of lifespan extension without co-solvent
utility in C. elegans [36], the employment of suitable co-solvent in
the culture system is important for elevating the in vivo compound
level to reach the pharmaceutical activity of the flavonoid. Another
notable condition for the compound test in the C. elegans system is
that liquid culture seems more effective for drug permeability in
vivo [16]. One possibility is that the compounds are absorbed more
efficiently through the penetration of hypodermics of worms in
liquid culture. DMSO is an important polar aprotic solvent that
dissolves both polar and nonpolar compounds. It is miscible in a
wide range of organic solvents as well as water and penetrates the
skin very readily. In our study, we use it as co-solvent combined
with liquid culture to maximize the penetration of the compounds.
In our system, final concentration of 1% DMSO was applied and
kept as the control treatment. For the further studies of icariin and
icariside II, suitable structure modification can be applied to
improve the bioavailability by increase its aqueous solubility.
Increased longevity is not only combating decrepitude but it is
also extending the health span, –the period of maintained general
health and vigor into late life [11]. Thus we tested a set of
parameters which indicate the healthlife upon drug treatment in C.
elegans. These parameters are constituted by the thermo and
oxidative stress resistance, the locomotion and the proteotoxicity.
Mutations that extend lifespan in invertebrates typically render the
animals resistant to multiple forms of external lethal injury [37].
Locomotion decline is a conserved hallmark of aging. It is thought
to be a major underling cause of loss of independence, frailty, and
morbidity [11]. The accumulation of structural damage to proteins
has been suggested to result in aging, like misfolding, denaturation
and aggregation [15,24,38]. Here, icariside II enhances the stress
tolerance, improving locomotion in late adulthood and amelio-
rating proteotoxicity in misfolding protein models. Taking
together, icariside II treatment leads to a healthspan.
For pharmacological intervention of lifespan, one possibility is
that compounds exposure may decrease the pathogenic of
bacterial, which have been shown to cause the longevity and
good fitness in late life [39]. In our system, this possibility is
excluded by adding antibiotics (Carbenicillin, 50 ug/ml) in the
Figure 5. Icariside II may not function as DR mimetic. Survival curves of A. eat-2 (ad1113),B .rsks-1 (ok1255) hermaphrodites treated with DMSO
control or 20 uM Icariside II is shown. Icariside II treatment caused similar lifespan extension in these mutants as in N2 animals. This is the
representative of 2 independent experiments. Detailed parameters are presented in Table S3.
doi:10.1371/journal.pone.0028835.g005
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effect, which is depicted as low exposure to stressors enhances the
damage repair mechanisms thus increase the lifespan [40]. The
possibility that the lifespan extension is the result of a hormetic
effect induced by the cytotoxicity of icariside II can also be ruled
out, since high doses of icariside II do not cause lethality (Figure
S5). Therefore, our data are more supportive for the specific
mechanisms of the lifespan extension effects of icariin and icariside
II.
Then how could icariside II introduces the beneficial effects
in C. elegans? These beneficial effects may be the result of an
inhibition of a mechanism that normally promotes aging. From
C. elegans to higher vertebrates, mutations in the insulin-like
receptor DAF-2 and its downstream component, PI3K/AKT/
PDK kinsases are the essential signaling to enhance longevity
and stress tolerance [12]. The FOXO-family transcription
factor DAF-16 is considered as the regulatory hub of these
phenotypes. Upon a reduction in IIS, DAF-16 is translocated
into the nucleus which is released from cytoplasm by the PI3K/
AKT/PDK kinase cascade, consorting the expression of the
target genes involved in life span control, stress tolerance and
protein homeostasis [41]. We proposed that the mechanism of
lifespan extension upon icariside II treatment was involved in by
IIS restriction in C. elegans. Our observations support the
proposal. We show that the life span extension is abolished in a
null daf-16 mutant and in a daf-2 allele suggesting that the
mechanisms of icariside II treatment may be overlapped by IIS
reduction. Furthermore, we find that icariside II treatment
significantly upregulates the mRNA expression of two of the
downstream targets of DAF-16 which indicates DAF-16 is
activated. Therefore, the IIS pathway is responsible for the
mechanisms of icariside II. Heat shock factor 1 (HSF-1)
activates transcription of heat-shock genes which encode
chaperones and proteases, in response to heat and other forms
of stress [15]. Global elevation of heat shock proteins (hsps) is
beneficial for the health longevity in IIS restriction background
in the invertebrate models [42]. Like DAF-16, HSF-1 is also
part of the DAF-2 pathway required for daf-2 mutants to live
long [15]. Our results show that icarisde II treatment does not
increase lifespan in hsf-1 mutant which indicates the HSF-1 is
required in the lifespan extension of the compound. Taking
together, the results indicate the healthspan extension induced
by icariside II via a DAF-2-DAF-16-HSF-1 pathway. As a
regulatory center in the lifespan control, several age-associated
pathways are directed to act through IIS. It is possible that
icariside II may target other pathways then reduces IIS. Recent
study shows a novel conserved pathway called EAK (enhancer-
of-akt-1) pathway acts parallel to the Akt/PKB kinases to
regulate the nuclear DAF-16/FOXO activity [43]. In drosoph-
ila, uncoupling protein (UCP) activity specified increased in the
insulin-producing neurons reduces IIS signaling and increase
lifespan [44]. Post translational modifications like intracellular
protein glycosylation is also reported to modulate insulin
mediated lifespan in C.elegans [ 4 5 ] .I n t e r e s t i n g l y ,K l o t h ow h i c h
exerts anti-aging properties in mammals, has been claimed to
function through DAF-2/DAF-16 signaling in C. elegans [46].
How icariside II restricts IIS to extend lifespan, it is still needed
to be investigated in future.
Our findings reveal a novel role for icariin, along with its
bioactive form icariside II in extending healthspan via the well
conserved pathway, IIS in C. elegans. Given the extensive protective
effects and safe long term use of icariin and icariside II in humans
[2], they may serve as promising anti-aging candidates in the
future.
Methods
Drug preparation
Icariin, icariside I, icariside II and icaritin were all from
Shanghai Winherb Medical Science Co., Ltd with purity (HPLC)
98%, 98.62%, 99.86% and 99.09% separately. All compounds
were maintained at 4uC in dark. 1006stock solutions were made
with 100% Dimethylsulfoxide (DMSO, Sigma; St. Louis, MO)
corresponding to each final concentration in the study. Before
adding, 1006stock solutions were diluted to a 106intermediate
solution with S basal freshly.
Strains
All C. elegans strains were maintained at 20uC as described in
previously [47], except that temperature-sensitive strains contain-
ing AM140, CL4176 and CB1370. The strains used were: N2
Bristol (wild type), PD4251 dpy-20(e1282) ccIs4251 [Pmyo-3NLS/
GFP, dpy-20(+)], AM140 (rmIs132[P(unc-54) Q35::YFP]), CL4176
(dvIs27[pAF29(myo-3/Ab 1-42/let UTR) + pRF4(rol-6(su1006)]),
CB1370 daf-2 (e1370), CF1038 daf-16(mu86), CF1553 muIs84
[pAD76(sod-3::GFP)], DA1116 eat-2(ad1116), SY3551 hsf-1(sy441),
XA8205 aak-2(ok524), XA8223 rsks-1(ok1255).
Lifespan analysis
Lifespan assay was performed in liquid medium [30] (S-
complete medium with 50 mg/ml carbenicillin and 0.1 mg/ml
fungizone) in 96-well plates containing, respectively, 150 ml total
volume,10–15 nematodes, and 6 mg/ml freshly prepared E. coli
OP50 per well. Age-synchronized nematodes were seeded as L1
larvae and plates were sealed with tape (Nunc) to prevent
evaporation. 5-fluoro-29-deoxyuridine (0.12 mM final) (Sigma)
was added 42–45 h after seeding to prevent self-fertilization.
Drugs were added 68 h after seeding (day 1 of adult life) unless
otherwise specified. Then the temperature was shifted from 20uC
to 25uC. Day 1 of the lifespan assay started 68 h after seeding the
animals into plates. The fraction of animals alive per well was
scored using a microscope on the basis of movement. Before
counting, each plate was put onto a plate rotator for 1–2 min.
Strong microscope light (visual) effectively stimulated movement
even in old animals. Using this assay, daf-16, daf-2 and eat-2
mutants showed alterations in lifespan similar to those reported
using agar plates.
Stress resistance assay
For thermotolerance assay, N2 were treated as the method
described in lifespan assay, except that the animals were transfer to
NGM at day 4 in adulthood. Then animals were put into 35uC
and counted every 2 hours. Animals that failed to respond to the
prodding against nose were defined as dead. For oxidative stress
resistance, N2 were treated as the method described in lifespan
assay, except that the animals were washed in M9 buffer 3–4 times
then soaked in hydrogen peroxide solution at 10, 15 and 20 mM
for 2 hrs at day 4 in adulthood at 20uC. After a 16 hrs recovery
period in NGM, survival worms were scored.
Swimming analysis and GFP-labeled muscle nuclei
quantitation
The assays were referred to [11]. Swimming assays were
performed at day 4 and day 10 in adulthood. The pre-treatment
was the same as the method described in lifespan assay, except that
worms in liquid culture were transferred to NGM plates spread
with E. coli one day ahead the swimming assay. Then individual
animals were transferred to 1 mL M9 buffer in a 24-well plate.
Icariside II Extends Healthspan via IIS Pathway
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bends during a 30-s trial using a stereomicroscope for observation.
A body bend was defined as a change in the reciprocating motion
of bending at the mid-body. Only animals that could move away
after a touch and could thrash were used for the swimming assay.
For quantitation of GFP-labeled muscle nuclei of the strain
PD4251, the pre-treatment is the same as in lifespan assay.
Animals were then paralyzed by 1 mM levamisole, mounted on
1% agarose pads and imaged using Olympus BX51 (606
objective) and HCImage software (Hamamatsu) at day 4 and
day 10. For counting the number of GFP-labeled nuclei in the
muscle, 15 animals were selected randomly to score the body
muscle nuclei. The representative images were given in Figure 2D.
High Performance Liquid Chromatography (HPLC)
The HPLC system is consisted of a chromatographic pump
(Agilent Technologies Series 1200 system, USA)), an autosampler
(Agilent, USA) equipped with a 100 mL sample loop, and a DAD
detector (Agilent, USA). Icariin, icariside I, icariside II and icaritin
were separated using a Waters SunFire
TM reversed-phase C18
column (150 mm64.6 mm, 5 mM) maintained at ambient tem-
perature (25uC). The mobile phase was consisted of acetonitrile
and 0.1% aqueous formic acid using gradient elution (0–2 min,
45–80% acetonitrile; 2–5 min, 80% acetonitrile; 5–5.1 min 80–
45% acetonitrile) and was delivered at a flow rate of 0.8 ml/min.
The mobile phase was filtered through a 0.45 mm Millipore
membrane filter prior to use. The DAD detection wavelength was
set at 270 nm, and output data from the detector were integrated
via a chemstation (Agilent, USA) chromatographic data system.
The standard samples of icariin, icariside I, icariside II and icaritin
were prepared in methanol at the concentration 10 mg/ml. The
current HPLC assay was validated for linearity, intra-day and
inter-day precisions, accuracy, extraction recovery and stability.
N2 were treated with 45 mM icariin for 4 days as previously stated
in lifespan assay. 350–400 worms were collected in M9 with 0.1%
sodium azide and washed in deionized water 4–6 times. Then
samples were homogenized using a glass stick homogenizator.
Samples were sonicated with 4 ml methanol for 10 min and
centrifuged at 12,000 rpm for 10 min. The pallet was extracted
twice in methanol. The supernatant was dried in a hood overnight
to evaporate the methanol. 200 ml methanol was added carefully
to dissolve the remaining residue. Then the solution was
centrifuged at 12,000 rpm for 10 min. At last 20 ml of the
resulting supernatant was filtered using a 0.45 mm syringe filter
prior to HPLC analysis.
Worm paralysis assays and polyQ aggregation
quantitation
For strain CL4176 dvIs2[pCL12(unc-54/humanAb3–42 minige-
ne)1pRF4], the method was referred to [20]. Staged populations
of CL4176 transgenic worms were prepared by synchronous egg
laying and induced to express Ab as third-stage larvae by upshift
from 15uCt o2 5 uC in NGM plates with or without drug
treatment. All paralysis plots were done in triplicate with 30–50
worms per condition. Nematodes were scored as paralyzed if they
exhibited ‘halos’ of cleared bacteria around their heads (indicative
of insufficient body movement to access food) or failed to undergo
a full body wave propagation upon prodding. For the strain
AM140 (rmIs132[P(unc-54) Q35::YFP]), synchronized L4 larvae
were transferred to NGM plates with DMSO or drug at 20uC.
Worms failed to move forward upon the tail prodding scored as
paralyzed. For photograph, animals were paralyzed with 1 mM
levamisole mounted on 1% agarose pads and imaged using
Olympus BX51 (606 objective) and HCImage software (Hama-
matsu) at day 4 and day 10. For polyQ aggregation quantitation,
15 worms from each group were randomly selected to be scored
for aggregates at day 4 and day 6. Aggregates were defined as
discrete structures with clear boundaries on all sides.
qRT-PCR assays
N2 animals were treated with DMSO or 20 mM icariside II for
4 days as described in lifespan assay. Then the day 4 adults were
collected for total RNA extractions using the Trizol reagent
(Invitrogen). The first strand cDNA was synthesized using the
reverse transcription system (Qiagen). SYBR Green dye (Quanta)
was used for qRT-PCR. Reactions were performed in triplicates
on an LC480 machine [48]. Relative-fold changes were calculated
using the 2
2DDCt method .
Western blot
For immunoblot analysis, day 4 adults were treated with DMSO
control or 20 mM icariside II as described above and replicates of
50 transgenic animals were collected for each treatment in 15 ml
HLB buffer (50 mM HEPES-KOH ph7.2; 150 mM NaCl; 1 mM
EDTA; 0.1%w/v Sodium deoxycholate; 1%v/v TritonX100;
0.1% SDS) with protease inhibitors . Gel electrophoresis, blotting
and detection of specific proteins were performed with standard
procedures. Detection and intensity quantitation was performed in
an odyssey Infrared Imaging System.
Supporting Information
Figure S1 Icariside I and icaritin do not extend lifespan
in N2. A. Survival curves of N2 hermaphrodites treated with
DMSO control or 20 mM icariside I from day 1 adulthood to
death at 25uC. B. Survival curves of N2 hermaphrodites treated
with DMSO control or 20 mM icaritin from day 1 adulthood to
death at 25uC. Presented is one of the duplicated experiments.
Statistical detail and repetitions of the experiments were
summarized in Table S1.
(PDF)
Figure S2 Icariin enhances thermo tolerance in N2
adults. Fractional survival percentages of day 4 adults (N2) at
the indicated time points at 35uC are increased significantly by
icariin treatment. Shown are average survival percentages in 3
experiments with 20–30 animals/experiment. Total number of
animals tested: 86 (DMSO Control), 79 (icariside II 20 mM); error
bars indicate SEM among three independent experiments; t-test,
*P,0.05,
**P,0.01.
(PDF)
Figure S3 Icariin treatment delay polyQ35-mediated
paralysis. Q35-GFP transgenic animals were treated with
DMSO control or 45 mM icariin from forth-stage larvae until
paralysis. Shown is the representative of two replicates. n=38
(control); 30 (icariin) animals, P=0.0464 (Log-rank (Mantel-Cox)
Test).
(PDF)
Figure S4 Icariin does not extend lifespan in daf-16 and
daf-2 mutants. Survival curves of N2, daf-2(e1370), and daf-
16(mu86) hermaphrodites treated with DMSO control or 45 mM
icariin are shown. Icariin treatment does not increase the life span
in daf-2(e1370) and daf-16(mu86) mutant but extends the life span
in N2. This is the representative of 2 independent experiments
with similar results. Detailed parameters are presented in Table
S2.
(PDF)
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in N2. Survival curves of N2 hermaphrodites treated with DMSO
control, 20 and 200 mM icariside II from day 1 adulthood to death
at 25uC.
(PDF)
Table S1 The effects of icariin and its derivates on
lifespan in N2. Mean lifespan of adults in days were observed in
lifespan analysis. The different concentrations of compounds
tested were indicated. Lifespan assays were performed at 25uC. ‘%
change’ was calculated by comparisons to DMSO control of the
same experiment. ‘N’ shows the number of observed deaths of
animals per experiment. P values were calculated by comparisons
to the survival curves of DMSO control of the same experiment
using long-rank tests. Individual experiment is listed. ‘*’ indicates
the sets of experiments plotted are shown in Figures. Survival
curves were plotted and statistical analyses were performed using
the Prism 5 software.
(DOC)
Table S2 Icariside II extends lifespan via insulin/IGF
pathway. Mean lifespan of adults in days were observed in
lifespan analysis. The different concentrations of compounds
tested were indicated. Lifespan assays were performed at 25uC. ‘%
change’ was calculated by comparisons to DMSO control of the
same experiment. ‘N’ shows the number of observed deaths of
animals per experiment. P values were calculated by comparisons
to the survival curves of DMSO control of the same experiment
using long-rank tests. Individual experiment is listed. ‘*’ indicates
the sets of experiments plotted are shown in Figures. Survival
curves were plotted and statistical analyses were performed using
the Prism 5 software.
(DOC)
Table S3 Icariside II does not function as DR mimetic.
Mean lifespan of adults in days were observed in lifespan analysis.
The different concentrations of compounds tested were indicated.
Lifespan assays were performed at 25uC. ‘% change’ was
calculated by comparisons to DMSO control of the same
experiment. ‘N’ shows the number of observed deaths of animals
per experiment. P values were calculated by comparisons to the
survival curves of DMSO control of the same experiment using
long-rank tests. Individual experiment is listed. ‘*’ indicates the sets
of experiments plotted are shown in Figures. Survival curves were
plotted and statistical analyses were performed using the Prism 5
software.
(DOC)
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